- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
First AREDS 2 AMD product hits market
Visual Advantage by Macular Health is the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.
Birmingham, AL-Visual Advantage by Macular Health has become the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.
Macular Health's original supplement formulation was modeled after the results of AREDS I, released in 2001. However, Jeffery McAnnally, president and chief executive officer of Macular Health, along with John O. Mason, III, MD, a retina surgeon from the University of Alabama at Birmingham Callahan Eye Foundation Hospital, modified the formula slightly to include lutein and zeaxanthin, which were ultimately proven by AREDS 2 to be the keys to the supplement's effectiveness.
Macular Health's Visual Advantage is specially formulated in the United States by an FDA inspected and GMP (Good Manufacturing Practices) compliant facility.
